Aldeyra Therapeutics, Inc. (ALDX)
Largest Insider Buys in Sector
ALDX Stock Price History Chart
ALDX Stock Performance
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in …
Insider Activity of Aldeyra Therapeutics, Inc.
Over the last 12 months, insiders at Aldeyra Therapeutics, Inc. have bought $2.77M and sold $851,621 worth of Aldeyra Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aldeyra Therapeutics, Inc. have bought $12.36M and sold $2.65M worth of stock each year.
Highest buying activity among insiders over the last 12 months: PERCEPTIVE ADVISORS LLC (10 percent owner) — $41.53M.
The last purchase of 37,712 shares for transaction amount of $178,755 was made by PERCEPTIVE ADVISORS LLC (10 percent owner) on 2024‑04‑05.
List of Insider Buy and Sell Transactions, Aldeyra Therapeutics, Inc.
| 2024-08-12 | Sale | Chief Development Officer | 16,041 0.0272% | $4.74 | $75,975 | +13.68% | ||
| 2024-08-12 | Sale | See Remarks | 10,834 0.0184% | $4.74 | $51,313 | +13.68% | ||
| 2024-04-05 | 10 percent owner | 37,712 0.0643% | $4.74 | $178,755 | -11.23% | |||
| 2024-04-04 | 10 percent owner | 140,281 0.2374% | $4.67 | $655,112 | -10.26% | |||
| 2024-04-03 | 10 percent owner | 309,847 0.5185% | $4.09 | $1.27M | +1.45% | |||
| 2024-04-02 | 10 percent owner | 186,051 0.3061% | $3.44 | $640,015 | +18.31% | |||
| 2024-04-01 | 10 percent owner | 8,374 0.0141% | $3.25 | $27,216 | +28.13% | |||
| 2024-03-12 | Sale | President and CEO | 85,324 0.147% | $3.05 | $260,238 | +38.37% | ||
| 2024-03-12 | Sale | Chief Development Officer | 11,537 0.0206% | $3.16 | $36,503 | +38.37% | ||
| 2024-03-11 | Sale | President and CEO | 97,914 0.1675% | $3.27 | $320,521 | +28.00% | ||
| 2024-03-11 | Sale | Chief Development Officer | 18,231 0.0324% | $3.41 | $62,102 | +28.00% | ||
| 2024-03-11 | Sale | See Remarks | 13,201 0.0235% | $3.41 | $44,968 | +28.00% | ||
| 2023-10-18 | Sale | 10 percent owner | 306,499 0.5276% | $1.74 | $533,308 | +109.83% | ||
| 2023-10-16 | Sale | 10 percent owner | 2.45M 3.6657% | $1.60 | $3.92M | +98.09% | ||
| 2023-04-12 | director | 509 0.0009% | $10.13 | $5,156 | ||||
| 2022-08-09 | 15,000 0.027% | $7.85 | $117,750 | -4.83% | ||||
| 2022-08-08 | 97,000 0.1669% | $7.24 | $702,280 | -1.53% | ||||
| 2022-08-05 | 141,000 0.2422% | $6.95 | $979,950 | +2.46% | ||||
| 2022-08-04 | 95,100 0.1609% | $6.17 | $586,767 | +13.46% | ||||
| 2022-08-03 | 100,000 0.1722% | $5.84 | $584,000 | +21.64% |
Insider Historical Profitability
| PERCEPTIVE ADVISORS LLC | 10 percent owner | 9275851 15.5767% | $4.72 | 18 | 2 | +4.58% |
| Brady Todd C | President and CEO | 1471298 2.4707% | $4.72 | 11 | 2 | +8.55% |
| EDELMAN JOSEPH | 11350085 19.0599% | $4.72 | 9 | 0 | +19.29% | |
| DOUGLAS RICHARD | director | 125000 0.2099% | $4.72 | 7 | 0 | +43% |
| Reed Joshua | Chief Financial Officer | 35774 0.0601% | $4.72 | 1 | 0 | +5.74% |
Institutional Investor Ownership
| Perceptive Advisors | $28.1M | 14.46 | 8.59M | 0% | +$0 | 0.02 | |
| Tupelo Capital Management LLC | $17.9M | 9.22 | 5.48M | 0% | +$0 | 0.44 | |
| The Vanguard Group | $12.65M | 6.51 | 3.87M | -1.49% | -$191,353.86 | <0.0001 | |
| BlackRock | $10.83M | 5.57 | 3.31M | -3.5% | -$392,357.51 | <0.0001 | |
| Kennedy Capital Management Inc | $4.31M | 2.22 | 1.32M | +3.29% | +$137,369.43 | 0.09 |